BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 34494499)

  • 1. An IDH-independent mechanism of DNA hypermethylation upon VHL inactivation in cancer.
    Artemov AV; Zhenilo S; Kaplun D; Starshin A; Sokolov A; Mazur AM; Szpotan J; Gawronski M; Modrzejewska M; Gackowski D; Prokhortchouk EB
    Epigenetics; 2022 Aug; 17(8):894-905. PubMed ID: 34494499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. VHL inactivation without hypoxia is sufficient to achieve genome hypermethylation.
    Artemov AV; Zhigalova N; Zhenilo S; Mazur AM; Prokhortchouk EB
    Sci Rep; 2018 Jul; 8(1):10667. PubMed ID: 30006568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different angiogenic potential in low and high grade sporadic clear cell renal cell carcinoma is not related to alterations in the von Hippel-Lindau gene.
    Baldewijns MM; van Vlodrop IJ; Smits KM; Vermeulen PB; Van den Eynden GG; Schot F; Roskams T; van Poppel H; van Engeland M; de Bruïne AP
    Cell Oncol; 2009; 31(5):371-82. PubMed ID: 19759417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis.
    Clifford SC; Prowse AH; Affara NA; Buys CH; Maher ER
    Genes Chromosomes Cancer; 1998 Jul; 22(3):200-9. PubMed ID: 9624531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma.
    Morrissey C; Martinez A; Zatyka M; Agathanggelou A; Honorio S; Astuti D; Morgan NV; Moch H; Richards FM; Kishida T; Yao M; Schraml P; Latif F; Maher ER
    Cancer Res; 2001 Oct; 61(19):7277-81. PubMed ID: 11585766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Consequences of VHL Loss on Global DNA Methylome.
    Robinson CM; Lefebvre F; Poon BP; Bousard A; Fan X; Lathrop M; Tost J; Kim WY; Riazalhosseini Y; Ohh M
    Sci Rep; 2018 Feb; 8(1):3313. PubMed ID: 29463811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors.
    Nickerson ML; Jaeger E; Shi Y; Durocher JA; Mahurkar S; Zaridze D; Matveev V; Janout V; Kollarova H; Bencko V; Navratilova M; Szeszenia-Dabrowska N; Mates D; Mukeria A; Holcatova I; Schmidt LS; Toro JR; Karami S; Hung R; Gerard GF; Linehan WM; Merino M; Zbar B; Boffetta P; Brennan P; Rothman N; Chow WH; Waldman FM; Moore LE
    Clin Cancer Res; 2008 Aug; 14(15):4726-34. PubMed ID: 18676741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unique molecular alteration patterns in von Hippel-Lindau (VHL) gene in a cohort of sporadic renal cell carcinoma patients from Pakistan.
    Khaliq S; Ajaz S; Firasat S; Shahid S; Hasan AS; Sultan G; Mohsin R; Hashmi A; Mubarak M; Naqvi SA; Rizvi SA; Mehdi SQ; Abid A
    Mutat Res; 2014; 763-764():45-52. PubMed ID: 24727139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct von Hippel-Lindau gene and hypoxia-regulated alterations in gene and protein expression patterns of renal cell carcinoma and their effects on metabolism.
    Leisz S; Schulz K; Erb S; Oefner P; Dettmer K; Mougiakakos D; Wang E; Marincola FM; Stehle F; Seliger B
    Oncotarget; 2015 May; 6(13):11395-406. PubMed ID: 25890500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The relationship of erythropoietin overexpression with von Hippel-Lindau tumour suppressor gene mutations between hypoxia-inducible factor-1α and -2α in sporadic clear cell renal carcinoma.
    Gong K; Zhang N; Zhang K; Na Y
    Int J Mol Med; 2010 Dec; 26(6):907-12. PubMed ID: 21042786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The von Hippel-Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C.
    Niu X; Zhang T; Liao L; Zhou L; Lindner DJ; Zhou M; Rini B; Yan Q; Yang H
    Oncogene; 2012 Feb; 31(6):776-86. PubMed ID: 21725364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of fibronectin and HIF-1alpha in renal cell carcinomas: relationship to von Hippel-Lindau gene inactivation.
    He Z; Liu S; Guo M; Mao J; Hughson MD
    Cancer Genet Cytogenet; 2004 Jul; 152(2):89-94. PubMed ID: 15262424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
    Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
    Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Germline polymorphisms in the Von Hippel-Lindau and Hypoxia-inducible factor 1-alpha genes, gene-environment and gene-gene interactions and renal cell cancer.
    van de Pol JAA; van den Brandt PA; van Engeland M; Godschalk RWL; van Schooten FJ; Hogervorst JGF; Schouten LJ
    Sci Rep; 2020 Jan; 10(1):137. PubMed ID: 31924838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic and epigenetic alterations in the von hippel-lindau gene: the influence on renal cancer prognosis.
    Smits KM; Schouten LJ; van Dijk BA; Hulsbergen-van de Kaa CA; Wouters KA; Oosterwijk E; van Engeland M; van den Brandt PA
    Clin Cancer Res; 2008 Feb; 14(3):782-7. PubMed ID: 18245539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alcohol consumption and mutations or promoter hypermethylation of the von Hippel-Lindau gene in renal cell carcinoma.
    Schouten LJ; van Dijk BA; Oosterwijk E; van Engeland M; Hulsbergen-van de Kaa CA; Kiemeney LA; Goldbohm RA; Kester A; de Vogel S; Schalken JA; van den Brandt PA
    Cancer Epidemiol Biomarkers Prev; 2008 Dec; 17(12):3543-50. PubMed ID: 19064569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling.
    Wykoff CC; Pugh CW; Maxwell PH; Harris AL; Ratcliffe PJ
    Oncogene; 2000 Dec; 19(54):6297-305. PubMed ID: 11175344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The VHL-dependent regulation of microRNAs in renal cancer.
    Neal CS; Michael MZ; Rawlings LH; Van der Hoek MB; Gleadle JM
    BMC Med; 2010 Oct; 8():64. PubMed ID: 20964835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
    Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
    Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. von Hippel-Lindau exonic methylation analysis using MALDI-TOF mass spectrometry.
    Lian F; Sreedharan S; Arnold RS; Master VA; Ogan K; Pattaras JG; Roberts DL; Petros JA
    J Urol; 2014 Nov; 192(5):1528-33. PubMed ID: 24704013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.